Truscreen Group Ltd. · NZX:TRU
Truscreen — Investor Presentation (March 2025)
33 slides from Truscreen's investor presentation, March 2025
Slide 1: TruScreen Investor Presentation March 2025
TruScreen Investor Presentation March 2025 1
Slide 2: TruScreen agenda
⚫ Who is TruScreen ⚫ The TruScreen Technology TruScreen ⚫ TruScreen Sales Strategy ⚫ TruScreen Key Financials ⚫ TruScreen - Our Journey and Growth Strategy ⚫ TruScreen Key Markets 2
Slide 3: Who is TruScreen
Who is TruScreen incer screening device wwwruscreen.com Ny truscree’ ASK DERM CE MTOMMOAMOMCSIOMNSTNI SE 3
Slide 4: Who is TruScreen
Who is TruScreen TruScreen Group Ltd is listed TruScreen Group Ltd is a on both the Australian (ASX) revenue generating Life and New Zealand (NZX) stock Science company with FY24 exchanges, with a common annual sales exceeding ticker code of TRU. NZD $2m. TruScreen Group Ltd owns Market Capitalisati
Slide 5: TruScreen Price History (NZX)
TruScreen Price History (NZX) Corporate Snapshot Major Shareholders Shares % New Zealand Depository Nominee 64,098,833 11.6 Shares on issue 552 million Consolidated Nominees 39,602,400 7.17 Options 13 million Masfen Securities Limited 29,050,369 5.26 Share price NZ$0.035 Bhagwanji Bhula Rama 27,791,
Slide 6: An Experienced Leadership Team
An Experienced Leadership Team TruScreen Group Ltd Mr. Anthony Ho Mr. Christopher Horn Ms. Juliet Hull Dr. Dexter Cheung B. Com (UNSW), CA, FAICD, B. Com (UNSW), FCA B.Nurse ATI, MBA MGSM B. Tech (Hons), M.Eng, PHD FCIS, FGIA Non-executive Independent Non-executive Director Non-executive Director No
Slide 7: An Experienced Leadership Team
An Experienced Leadership Team TruScreen Group Ltd Mr Marty Dillon Mr. Guy Robertson Professor Michael Campion CEO B. Com (Hons.) CA Medical Advisory Committee Chair CFO & Company Secretary • Martin Dillon, the CEO of TruScreen Group • Professor Michael Campion graduated from the Ltd, skilfully mana
Slide 8: About TruScreen Technology
About TruScreen Technology Enable by AI, TruScreen provides an accurate, real time cervical cancer screening solution 8
Slide 9: TruScreen real-time AI-enabled cervical cancer screening device
Real-time, AI-enabled, primary cervical cancer TruScreen screening device for detection of pre-cancerous and cancerous cervical tissue What is the TRU System and how does it work? The TRU system consists of a handheld device (HHD), intelligent cradle and a single-use-sensor (SUS). Handheld device Th
Slide 10: Optical and Electrical Tissue Differentiation
Optical and Electrical Tissue Differentiation Optical Tissue Differentiation Electrical Tissue Differentiation TruScreen measures the Squamous tissue acts as a battery and stores, scattering and diffuse reflection for a brief period, electrical charge. of Distant Red, Red, Infrared and Green light.
Slide 11: Trusted Clinical Performance
Trusted Clinical Performance Extensive body of High sensitivity in High specificity in clinical evidence detecting CIN2+* detecting CIN2+* See Appendix for a full list of clinical trials TruScreen® has been TruScreen® has been Over 40,000 found to be as sensitive found to be more women in clinical i
Slide 12: Why Choose TruScreen
Why Choose TruScreen TruScreen 12
Slide 13: TruScreen Sales Strategy
TruScreen Sales ___. Strategy wwwetruscreen.com Iso céE NATIONAL MEDICAL PRODUCTS ADMINISTRATION = SS” 13 DRASKHEER 13485
Slide 14: Recurring Revenue Model
Recurring Revenue Model TruScreen manufactures two devices - one made in China for use in China, where locally manufactured products have preferential market access, and one made in Australia for other markets For each patient screened with the TruScreen device a new disposable Single Use Sensor (SU
Slide 15: TruScreen Financials
TruScreen Financials FY 24 v FY 23 KEY FINANCIALS FY 22 FY 23 FY 24 NZD (m) Actual Actual Actual ⚫ Sales increased 27% YOY Sales 1.7 1.66 2.1 ⚫ SUS Sales increased 25% YOY Total Revenue 2.7 2.2 2.6 COGS 1.3 1.3 1.4 ⚫ Revenue increased 18% YOY R&D 1.5 0.9 0.9 EBITDA -2.7 -2.4 -2.0 ⚫ EBITDA improved 1
Slide 16: TruScreen Financials
TruScreen Financials 1st Half FY24 1st Half FY25 % Change Sales $0.98 $1.03 5% EBITDA -$1.35 -$1.13 16% Operating Cash Outflow -$1.4 - $0.9 36% SUS Units 91,620 96,480 5% Devices 42 9 -79% China SUS pull though per month per device 97 137 41% 16
Slide 17: TruScreen Journey
TruScreen Journey Building the Fundamentals 2014 - 2020 Building for the Future 2020-2024 2025 & Beyond 2022 China Growth continues Managing COVID-19 challenges CFDA (NMPA) Distribution of Dalton Bio IVD HPV approval for Cost reduction DNA products second generat ion Manufacturing and business devic
Slide 18: Market Expansion
Market Expansion FY 24 TruScreen sales grow 27% YOY, exceeding China and APAC CAGR forecasts for HPV screening (10%). HPV Test Market Revenue (Million USD) and Growth Rate (2018-2028) Business Market Insights June 2023: The Asia Pacific CIN & HR-HPV treatment market is expected to grow from US$ 2,73
Slide 19: Device installations and SUS Sales
Device installations and SUS Sales 'SUS Usage', 'Installed Devices' by 'Field1' 300 350 Thousands Where we are 300 250 250 200 Installed Devices 200 SUS Usage 150 150 100 100 50 50 0 0 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 Field1 Installed Devices SUS Sales This is not a forecast of performance or
Slide 20: Growth Strategies
Growth Strategies Focus on key growth provinces Strengthen China Market expansion to Shandong, Jiangsu, Distribution Capability via continue with China the Guangdong, Hunan, Strategic Partnership with key focus Zhejiang, Guangxi DaltonBio (Total popn 496m) Build on International Target Govt and NGO
Slide 21: Growth Strategies
Growth Strategies Developing strategic Capitalise on global focus Focus on countries with partnerships for on AI enabled cervical limited or nil cervical complementary woman’s cancer technologies – e.g screening capability health services WHO Expand product portfolio to include Dalton Bio HPV Reduce
Slide 22: TruScreen & Dalton Bioscience
TruScreen & Dalton Bioscience • MOU signed February 2025 between TruScreen Group Ltd and Hangzhou Dalton Bioscience • Collaborate for expansion: 1. TruScreen to distribute globally (excluding USA and Canada) via selected distributors DaltonBio HPV related IVD products including DNA tests and Self Sa
Slide 23: TruScreen's presence and global markets
TruScreen’s presence and global markets* RUSSIA 48M & CENTRAL ASIA 13M China UZBEKISTAN 477M MEXICO SAUDI 12M 46M 11M VIETNAM 36M ASEAN & INDONESIA SOUTHERN 142M & CENTRAL AFRICA INDIA 134M 468M * Number of eligible women to of screening age: CIA World Fact Book Women 15-64, Current Markets Targetin
Slide 24: China: TruScreen's largest market and No 1 focus for sales
Over 477 million women of screening age, with 158 million women needing to be screened each year* China High government support for cervical cancer screening TruScreen’s largest market and No 1 Focus for Sales Made in China status from 2021 – preferred market access in China – NMPA approval * CIA Wo
Slide 25: China
China China Sales represented 78% of FY2024 Global Sales. This is a result of a continued focus by TruScreen as our key target market and years of pushing to have TruScreen recognized by key institutions as a recommended method for the primary screening for cervical cancer. Inclusion in Official Scr
Slide 26: China
China Beijing has approved TruScreen Provincial Pricing Approvals from 11 for a Public Health Scheme Rebate 25 Hospitals currently in tender process to procure TruScreen Provincial Pricing Approvals submitted: 10 TruScreen installed in Affiliated Hospital of Nantong University the leading hospital i
Slide 27: Vietnam
Vietnam April 12, 2025: Launch of Ho Chi Minh City Public Health Association (HPHA) screening program. 36 million women of The HPHA will conduct of a 5-year program screening at least 260,000 women in Ho Chi screening age* Minh City. The project, titled ‘Community Based Proactive Cervical Cancer Scr
Slide 28: South East Asia and Uzbekistan
South East Asia ASEAN and Indonesia Distribution TruScreen has distribution for Thailand, Singapore and Malaysia. This will give TruScreen a continuous geographic East Asian market from Indonesia (where product registration has recently been approved), through the ASEAN region, Indo- China and 142 m
Slide 29: Zimbabwe and Mexico
Zimbabwe Use in Public Screening Campaign Zimbabwe accounted for 17% of TruScreen’s global sales in FY2024 and TruScreen continues to work with the Ministry of Health and the National Aids Council to expand on 17 million women of our screening in Masvingo province, where 14,000 women have been scree
Slide 30: Russia and Central Asia, Saudi Arabia
Russia and Central Asia 61 million women In October 2024 TruScreen was included in the Russian Cervical Cancer Screening Guideline of screening age (listed as an ‘opto-electric screening device’) and TruScreen’s Russian distributor is also expanding activities to include Kazakhstan, Kyrgyzstan, Bela
Slide 31: Contact us for more Information
Contact us for more Information Martin Dillon Guy Robertson CEO Chief Financial Officer M - +61 449 115 065 M – +61 407 983 270 E – martindillon@truscreen.com E – guyrobertson@truscreen.com TruScreen TruScreen Suite 3.03 18 Orion Rd Suite 3.03 18 Orion Rd Lane Cove West NSW 2066 Lane Cove West NSW 2
Slide 32: Disclaimers
Disclaimers This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 25 August 2023. This presentation contains summary information about the Company and its activities which is current as at the date of this presentation. The information in this presentation is of
Slide 33: References
References 1. WHO, HPV and Cervical Cancer Fact sheet, 11 November 2020, https://www.who.int/news- room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer 2. WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), 2020 3. Human papillomavirus and cancer (who.int) 4. Wei, Y., Wan